glp 1 for weight loss Top GLP-1 Agonists Balance Efficacy, Safety Questions about GLP-1s? A Providence

Retrieved 2022-12-12

N/A (Khavinson bioregulator) For in-vitro research use only

The cGAS-STING-YY1 axis accelerates progression of neurodegeneration in a mouse model of Parkinsons disease via LCN2-dependent astrocyte senescence

1 month (30 days), and 3 months (90 days) after FMT and ICI initiation), stratified by progression status

Important safety considerations include contraindications in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, caution in those with a history of pancreatitis, increased risk of gallbladder disease, potential for acute kidney injury with dehydration, and possible worsening of diabetic retinopathy with rapid glycemic improvement